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Background. Diagnosis and timely treatment of tuberculosis in children is hampered by the absence of fast
and reliable tests, especially in the era of human immunodeficiency virus (HIV). The aim of this study was to
evaluate the diagnostic performance of the Xpert MTB/RIF assay (Xpert) in children with suspected tuberculosis
in a high tuberculosis/HIV-burden setting.
Methods. In a prospective study with a minimum follow-up of 12 months, 164 children with suspected
tuberculosis were assigned to predefined diagnostic subgroups, based on microbiological and clinical findings.
Results of smear microscopy and culture were compared against diagnostic performance of Xpert.
Results. Twenty-eight of 164 children (17.1%) had confirmed tuberculosis. Xpert detected 100% (95%
confidence interval [CI], 59.0%–100%) of smear-positive cases and 66.6% (95% CI, 43.0%–85.4%) of culture-
positive but smear-negative cases. In the per-sample analysis, Xpert displayed a similar sensitivity (54.7% [95% CI,
42.7%–66.2%]) compared with culture methods. Xpert detected 3-fold more confirmed tuberculosis cases than
smear microscopy but with equal rapidity. Four additional cases (8.5%) with clinical tuberculosis but negative
culture were diagnosed by Xpert. Testing second and third samples increased sensitivity by 20% and an additional
16%, respectively. When tuberculosis was reliably excluded, Xpert’s specificity was 100%. HIV infection did not
affect diagnostic accuracy of Xpert.
Conclusions. Xpert was easy to perform and displayed similar diagnostic accuracy as culture methods in
children with suspected tuberculosis. Rapid turnaround times should reduce treatment delay and improve
patient outcome, although sensitivity remains suboptimal and access is dependent on local laboratory
infrastructure.
Due to the paucibacillary nature of tuberculosis dis-
ease in children and the absence of reliable diagnostic
methods, tuberculosis diagnosis in children remains
a great challenge. Even under optimized conditions,
smear microscopy, which is the standard diagnostic
method in developing countries, is positive in ,10%–
15% of children with suspected tuberculosis [1, 2].
Likewise, culture—which is considered the gold stan-
dard in adult tuberculosis diagnosis—has been shown
to be insensitive in children because it remains negative
in 20%–80% of all childhood tuberculosis cases, de-
pending on the manifestation and the stage of the disease
[1, 3–5]. The tuberculin skin test, although helpful in
certain settings, cannot differentiate between latent and
active tuberculosis disease [6, 7]. Therefore, tuberculosis
diagnosis in resource-limited, tuberculosis-endemic
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countries is mainly based on clinical and radiological findings,
as well as medical history [8].
New methodologies to improve tuberculosis diagnosis in
children have been described recently [6, 9]. Among them are
refined clinical scoring [10, 11], enhanced techniques of sample
collection [2, 12], and new microbiological and immuno-
logical methods [13–15]. In particular, the development of
nucleic acid amplification tests (NAATs) holds promise.
However, although several studies on diagnostic accuracy
of (commercial) NAATs in adults were published with con-
siderably heterogeneous results [13, 16], very few data are
available on children [15, 17].
In December 2010, the Xpert MTB/RIF assay (Xpert;
Cepheid) was endorsed by the World Health Organization
(WHO) for direct tuberculosis screening on sputum samples
[18]. This test features many advantages compared with other
commercial NAATs, including the possibility for parallel de-
tection of Mycobacterium tuberculosis and resistance to rifam-
picin, a hands-free cartridge system that can be used after only
a brief training period, and a time to result of approximately
2 hours [19]. The Xpert was evaluated in clinical trials in
adults, and most recently also in children with suspected tu-
berculosis, and showed good sensitivity and specificity in
smear-positive and culture-positive and reasonable accuracy in
smear-negative but culture-positive sputum samples [20–23].
Looking at these data, as well as the excellent technical char-
acteristics, the assay might be considered a promising di-
agnostic test in childhood tuberculosis that is simple enough
to be used outside central laboratories, and thus could be
operated closer to the patients. The aim of this study was to
explore the diagnostic performance of the Xpert and to esti-
mate its impact on time to diagnosis and treatment initiation
in a cohort of children with suspected tuberculosis in a tu-
berculosis/human immunodeficiency virus (HIV)–endemic,
resource-constrained setting.
METHODS
Ethical Approval and Informed Consent
The study was approved by the local Mbeya Medical Research
and Ethics Committee and the National Ethical Committee at
the National Institute of Medical Research (NIMR) in Tanzania.
Written informed consent for all children was obtained from an
accompanying parent or a legal guardian. In addition, children
aged $9 years signed an assent form.
Study Setting
The study was conducted at the NIMR-Mbeya Medical Research
Programme (MMRP) in close collaboration with the Mbeya
Referral Hospital (MRH). The Mbeya region (located in
southwest Tanzania) has a high burden of tuberculosis and
HIV, with approximately 3600 cases of tuberculosis detected
in 2006, and an HIV prevalence of 16.6% in people between
15 and 49 years of age [24]. HIV prevalence in children
2–15 years of age was 1.5% across the region (our unpublished
data, 2006–2009).
Study Population and Clinical Procedures
One hundred eighty children aged 6 weeks to 14 years with
clinical signs of tuberculosis were enrolled in the study and
prospectively followed up for a minimum of 12 months. All
children had at least 1 of the following symptoms: persistent,
unremitting cough for .21 days; repeated episodes of fever
within the last 21 days; weight loss or failure to thrive within
the previous 3 months; or signs and symptoms suggestive of
extrapulmonary tuberculosis. Children who had received tu-
berculosis treatment within the last 3 months were excluded
from the study. Whereas 140 children sought healthcare on
their parents’ initiative and presented to the MRH, 40 children
with tuberculosis symptoms were identified through contact
tracing of smear-positive relatives. Sixty-nine children were
recruited while hospitalized.
Recruitment procedures comprised interviews regarding
medical history and full clinical examination, both according
to standardized data recording forms, anterior-posterior chest
radiography, blood sample collection, and HIV pre- and
posttest counseling (data-capturing forms are available as
online Supplementary Material 1). Anthropometric data were
measured at baseline, and each follow-up visit and corre-
sponding z scores were calculated to monitor the nutritional
status of the children, using the WHO child growth standards
data as a reference [25, 26]. All study participants underwent
a tuberculin skin test (TST) in a standardized fashion [14].
At baseline, every patient provided up to 3 sputum samples for
analysis. In 41.5% of children who were unable to produce
a sputum sample spontaneously, induced sputum was ob-
tained in accordance with standardized protocol. Other clinical
specimens for microbiological investigations were collected if
possible and if clinically indicated.
Based on clinical, radiological, and microbiological findings
at baseline and during follow-up, 164 children were assigned
to predefined diagnostic classification groups as described
previously [14] (Figure 1). Follow-up visits were scheduled at
3, 6, and 12 months after enrollment or in case of tuberculosis
treatment at 3, 6, and 12 months after treatment initiation.
Patients were asked to make unscheduled visits in case their
clinical condition deteriorated.
A decision on tuberculosis treatment initiation was made in
liaison with the pediatric department of the MRH and the
District Tuberculosis and Leprosy Coordinators and was
based on microbiological or histological data, clinical findings
(including TST and chest radiography), and clinical history.
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Xpert results were not included in the diagnostic algorithm.
Antituberculosis therapy was administered following Tanzanian
National Guidelines. Patients diagnosed with HIV infection
were referred for further staging and treatment to the relevant
HIV Care and Treatment Centers.
Laboratory Procedures
Untreated sputum samples were vortexed for 5 minutes and split
into 2 aliquots; 1 was stored at 220C and the other was de-
contaminated by the N-acetyl-L-cysteine–sodium hydroxide
(NALC-NaOH) method (see Supplementary Figure 1). In brief,
the sample was mixed with an equal volume of NALC-NaOH
(0.5% NALC, 2% NaOH, 1.45% sodium citrate), incubated at
room temperature for 20 minutes, and neutralized with
phosphate-buffered saline (total volume, 50 mL). After cen-
trifugation (3500g, 20 minutes, 4C), the resulting pellet was
processed for standard sputum microscopy after Ziehl-Neelsen
staining and culture on both Lowenstein-Jensen media (LJ)
and BACTEC MGIT 960 liquid culture (Becton Dickinson).
Species determination was performed by Genotype Myco-
bacterium MTBC, CM, and AS tests (Hain Lifescience). Drug
susceptibility was tested using SIRE test kits in the BACTEC
MGIT system. The remaining decontaminated sputum pellet
was stored at 220C.
Laboratory personnel involved in the evaluation of Xpert
were blinded for all other laboratory results of the relevant
sputum sample and corresponding clinical diagnosis. All sputum
samples tested by Xpert assay were processed according to the
manufacturer’s instructions [19].
Statistical Analysis
Stata (version 11; StataCorp) was used for data analysis and
to produce graphs. First, diagnostic performance of Xpert
was compared with the primary reference standard, which
was at least 1 M. tuberculosis–positive culture in up to 3 col-
lected respiratory samples. In addition, Xpert performance
(and performance of other microbiological tests) was com-
pared with clinical diagnosis of tuberculosis. Confidence
intervals (CIs) for the mean (eg, sensitivity and negative
predictive value) of binary variables were calculated using
the formula for exact binomial CIs. Probability values to
compare whether the diagnostic performance of Xpert
(eg, sensitivity) was significantly different from the perfor-
mance of the other methods were calculated using McNemar
test. Associations between Xpert positivity (binary outcome
variable) and other factors were assessed using univariable
and multivariable Poisson regression models with robust
(Huber-White) variance estimates adjusted for clustering
Figure 1. Diagnostic classification of children presenting with suspected tuberculosis. *In total, 469 sputum samples, 2 pleural fluid samples, 1 sample
from lymph node aspiration, and 1 ascites sample were obtained for microbiological investigations. No gastric aspirates were collected. Abbreviations:
CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; TST, tuberculin skin test.
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by participant [27, 28]. All P values reported in this manu-
script are 2-sided.
RESULTS
One hundred eighty children with suspected tuberculosis
were enrolled between May 2008 and November 2010. Sixteen
participants with an incomplete set of data were excluded
from further analysis, and 164 children were assigned to 1 of
the 4 predefined diagnostic classification groups (Figure 2).
Demographical and clinical data of all children at the time of
enrollment are displayed in Table 1.
Twenty-eight of 164 children (17.1%) had microbiologi-
cally confirmed tuberculosis with at least 1 culture positive
for M. tuberculosis. The Xpert detected 21 (75%; 95% CI,
55.1%–89.3%) of these culture-confirmed tuberculosis cases,
with 100% sensitivity (95% CI, 59.0%–100%) in the 7 smear-
positive children and with 66.6% sensitivity (14 of 21 children;
95% CI, 43.0%–85.4%) in the culture-positive but smear-
negative children (Table 2). Compared with LJ and MGIT alone,
Xpert diagnosed 82.6% (95% CI, 65.8%–99.4%) of LJ-positive
and 83.3% (95% CI, 67.3%–99.4%) of MGIT-positive cases.
The per-sample analysis of the 77 sputum samples collected
from class I illustrates the limitations of all diagnostic tests
to consistently find M. tuberculosis in the sputa of children
with microbiologically confirmed tuberculosis. Whereas smear
microscopy detected tuberculosis in only 19.5% of cases,
solid and liquid culture and Xpert had a sensitivity of 55.3%,
54.7%, and 54.7%, respectively. Notably, not all assays were
positive in the same samples, and as a consequence the com-
bination of all diagnostic tests increased the overall sensitivity
to 77.9% (Supplementary Table 1).
Of the 47 children in class II with clinical tuberculosis
diagnosis but no microbiological proof, 4 cases (8.5% of 47)
were detected by Xpert. According to the definition of
the clinical classification, these children had a very high
likelihood of active tuberculosis and therefore may be as-
sumed as correctly diagnosed tuberculosis cases. Thus, Xpert
increased the total diagnostic sensitivity by 5.4% from 37.3%
to 42.7% (Table 2). It is important to note that in class I
Figure 2. Recruitment and diagnostic classifications of participants. *Twenty-eight children had microbiological confirmation of Mycobacterium
tuberculosis, of whom 7 were positive on acid-fast stains. Twenty-four of 28 children showed sustained clinical improvement after initiation of
antituberculosis therapy. Two children were lost to follow-up, and 2 children died either immediately after baseline investigations or soon after
tuberculosis treatment initiation. Forty-seven children had highly probable tuberculosis, although no microbiological confirmation was possible; of
these, 34 showed sustained clinical improvement after tuberculosis treatment initiation; 2 children were lost to follow-up before treatment could be
started; and 4 children died during treatment; 2 children died before treatment could be initiated, and 5 children died despite taking tuberculosis
medication during the course of the study. Abbreviations: TST, tuberculin skin test; Xpert, Xpert MTB/RIF assay.
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Table 1. Demographic and Clinical Characteristics of Children by Clinical Classification Group
Diagnostic Class
I II III IV Excluded All Classes
No. 28 47 67 22 13b 177b
Sex (% male) 35.7 44.7 61.2 59.1 58.3 52.3
HIV prevalence (%) 56 57.4 50.8 42.9 30.0 51.2
Median CD4 count in
HIV-positive children (IQR)
479 (284–690) 360 (68–563) 581 (326–949) 482 (233–646) 1077 (417–1202) 489 (263–773)
TST reactive (%) 56.5 43.2 36.2 0.0 22.2 35.3
TST reactive in HIV-positive
children (%)
45.5 11.5 24.1 0.0 0.0 19.2
TST reactive in HIV-negative
children (%)
70.0 88.9 48.1 0.0 33.3 52.1
Median age, y (IQR) 6.4 (2.0–11.0) 6.1 (2.5–9.4) 5.1 (2.4–9.0) 5.5 (2.6–10.3) 5.9 (1.9–11.8) 5.8 (2.4–9.4)
Median weight for age,
z scorea (IQR)
22.4 (23.8 to 20.4) 21.6 (22.6 to 20.8) 22.0 (23.1 to 21.1) 21.8 (23.8 to 20.9) 21.8 (22.9 to 20.3) 21.9 (23.2 to 20.9)
Median BMI for age,
z score (IQR)
21.2 (22.5 to 20.0) 0.0 (21.2 to 0.7) 20.7 (22.3 to 0.4) 20.9 (21.9 to 0.3) 21.0 (21.5 to 0.6) 20.7 (21.9 to 0.3)
1-y mortality (%) 7.7 17.1 10.9 0 . .
Sputum induction in age
groups (% induced)
,2 100.0 100.0 90.9 100.0 100.0 97.2
2–4 100.0 71.4 75.0 75.0 100.0 75.8
5–9 0.0 4.5 12.5 14.3 0.0 8.2
$10 0.0 0.0 12.5 0.0 0.0 3.4
Total 34.8 36.4 46.0 42.9 50.0 41.5
Site of tuberculosis for clinical classification I [29]: 28 children with intrathoracic tuberculosis: 10 hiliar lymphadenopathy, 4 lymphobronchial tuberculosis, 6 tuberculous bronchopneumonia, 1 miliary tuberculosis, 4
tuberculous pleural effusion; 3 children had no radiograph but had Mycobacterium tuberculosis–positive sputum culture. Site of tuberculosis for clinical classification II [29]: 46 children with intrathoracic tuberculosis: 10
hiliar lymphadenopathy, 12 lymphobronchial tuberculosis, 12 tuberculous bronchopneumonia, 5 miliary tuberculosis, 6 tuberculous pleural effusion, 1 primary cavitating pulmonary tuberculosis; 1 child had inguinal
tuberculosis adenitis.
Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus; IQR, interquartile range; TST, tuberculin skin test.
a Only available for children aged #10 years due to lack of reference data for older children.

















and class II combined, sensitivity of the Xpert assay was higher
than that of solid culture or liquid culture alone, both in the
per-patient and the per-sample analyses (Table 2; Supplementary
Table 1), although this difference was not significant.
When analyzing all received samples (214) in class I and II in
order of their collection, there was a substantial gain in sensi-
tivity when a second sample was evaluated (Figure 3). This
observation was valid for all diagnostic assays: the incremental
yield was at least 14.3% for smear (1 case) and maximal 29.2%
(7 cases) for MGIT. In case of a third sample analyzed, the
incremental yield was 13% (3 cases) for LJ and 16% (4 cases)
for Xpert. However, if all methods had been applied in parallel,
26 of 32 detected cases would have already been identified in
the first sample.
Figure 3. Gain in cases per additional analyzed sample. Number of additional cases detected by analyzing a second and third sample from study
participants in diagnostic classes I and II (n5 75), displayed for each diagnostic test. In 65 children, 3 samples were collected; 9 children gave 2 samples;
and in 1 child only 1 sample was collected. Abbreviations: LJ, Lowenstein-Jensen culture on solid media, speciation result included; MGIT, BACTEC MGIT
960 liquid culture, speciation result included; smear, sputum smear microscopy after Ziehl-Neelsen staining; Xpert, Xpert MTB/RIF assay.
Table 2. Sensitivity of Each Diagnostic Test in Per-Patient Analysisa,b
Diagnostic Class (no.)
I (28) II (47) I and II Combined (75) III (67)c
Diagnostic Test
Positive, no., %,
(95% CI), P Value
Positive, no., %,
(95% CI), P Value
Positive, no., %,
(95% CI), P Value
Positive, no., %,
(95% CI)
Smear 7 25.0 (10.7–44.9) ,.001 0 0.0 (.0–7.5) .125 7 9.3 (3.8–18.3) ,.001 0 0.0 (.0–5.4)
MGIT 24 85.7 (67.3–96.0) .375 0 0.0 (.0–7.5) .125 24 32.0 (21.7–43.8) 1.000 0 0.0 (.0–5.4)
LJ 23 82.1 (63.1–93.9) .688 0 0.0 (.0–7.5) .125 23 30.7 (20.5–42.4) .754 0 0.0 (.0–5.5)
Xpert 21 75.0 (55.1–89.3) . 4 8.5 (2.4–20.4) . 25 33.3 (22.9–45.2) . 0 0.0 (.0–5.4)
MGIT and LJ 28 100 (87.7–100) .016 0 0.0 (.0–7.5) .125 28 37.3 (26.4–49.3) .549 0 0.0 (.0–5.4)
MGIT, LJ, and Xpert 28 100 (87.7–100) .016 4 8.5 (2.4–20.4) 1.000 32 42.7 (31.3–54.6) .016 0 0.0 (.0–5.4)
Abbreviations: CI, confidence interval; LJ, Lowenstein-Jensen culture on solid media, includes speciation result; MGIT, BACTEC MGIT 960 liquid culture, includes
speciation result; smear, sputum smear microscopy after Ziehl-Neelsen staining; Xpert, Xpert MTB/RIF assay; %, sensitivity of diagnostic test in percentage.
a False-positive rate (the percentage of positives in diagnostic class IV) was 0% for all diagnostic tests.
b Positive predictive value was 100% for all diagnostic tests; negative predictive value for each diagnostic test can be found in Supplementary Table 2A.
c In clinical class III, LJ was performed in only 65 children.
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If compared with culture as reference standard (class I, 77
samples), sensitivity of Xpert was 46.4% in the first sample vs
75% sensitivity in culture (LJ and MGIT combined). Xpert’s
sensitivity rose to 60.7% vs 96.4% for culture and 75% vs
100% for culture, respectively, if second and third samples
were analyzed (data not shown).
Univariable and multivariable Poisson regression showed that
a higher age and an increased severity of clinical condition were
significantly associated with Xpert positivity. Other variables
such as HIV status or sample status might have influenced
Xpert performance to a certain degree, although none of these
associations were significant when adjusted for other variables.
Notably, in univariable analysis, induced sputum samples were
found significantly less often to be Xpert positive than non-
induced sputum samples. However, when adjusted for age,
induced sputum samples appeared .4 times more likely to be
Xpert positive than noninduced sputum samples (Supple-
mentary Table 3).
Xpert identified no child in class IV as positive, which resulted
in a false-positive rate of 0%. In addition, of 26 sputum samples
growing nontuberculosis mycobacteria on solid or in liquid
culture, none were reported as positive by Xpert. In concordance
with the results of resistance testing in liquid culture, there was
no rifampicin resistance detected by Xpert.
Median time from enrollment to detection of tuberculosis
was 1 (range, 1–3) day for smear, 21 (range, 11–59) days for
MGIT, and 30 (range, 14–79) days for LJ (Figure 4) for patients
in clinical class I. Assuming that Xpert results would be available
at the latest 1 day after sample collection (sample turnaround
time of 1 day), the median time from enrollment to tuberculosis
diagnosis would be 2 (range, 1–12) days for Xpert. The slight
difference compared with microscopy reflects the fact that
Xpert, as opposed to smear, has the capacity to detect cases
with lower bacterial load that were only identified in the
second and third samples [21, 30].
The median time to tuberculosis treatment initiation in
classes I and II was 8.5 days (range, 0–77) and 17 days (range,
1–745), respectively. Although for all children in class I a mi-
crobiologically confirmed diagnosis was finally existent, lab-
oratory results were the basis for treatment initiation in only
16 of 28 children (57.1%). Seven of these 16 children were
smear positive and received treatment within 1 week after
enrollment. In the remaining 9 children, antituberculosis
therapy was started within 15–59 days after obtaining
a positive-culture result. Two of 28 children (7.1%) children
in class I did not receive treatment because they were lost
to follow-up while culture results were pending for.1 month.
Assuming that the interval from a positive result in the labo-
ratory to treatment initiation in the clinic would be similar
for Xpert and microscopy (1.7 days), it was calculated that 25%
of all Xpert-positive cases could have received tuberculosis
treatment 31 or more days earlier, and 50% of them could have
received treatment 6 or more days earlier, if Xpert had been
included in the diagnostic algorithm.
DISCUSSION
Worldwide, the majority of tuberculosis in children is diagnosed
and treated on clinical grounds. This is not only due to the
constrained diagnostic capacities in most tuberculosis-endemic
countries, but also because of multiple shortcomings of the
current diagnostic tests in childhood tuberculosis. Here, we
present data on a clinical evaluation of Xpert in children. Our
study was performed in a high tuberculosis/HIV-burden set-
ting, where .50% of the study participants were HIV-positive.
In this prospective study, we consecutively enrolled children
suspected of having tuberculosis at the moment of their
presentation to the healthcare system, without applying any
preselection. A long follow-up period of at least 12 months up
Figure 4. Proportion of detected tuberculosis cases versus time to
tuberculosis detection. Proportion of detected tuberculosis cases by each
diagnostic test and test combinations displayed as percentages of all
tuberculosis cases (children in diagnostic classes I and II combined,
n5 75). Time to tuberculosis detection was considered as the number of
days from enrollment until positive tuberculosis test result was received
in the tuberculosis laboratory. For calculations in Xpert, a sample
turnaround time of 1 day (similar to smear microscopy) was considered.
All collected samples were included: in 65 children, 3 samples were
collected; in 9 children, 2 samples were collected; and in 1 child, only 1
sample was collected. Results positive by a certain test if at least 1 of up
to 3 collected samples was positive. Seven (9.3%; 95% confidence
interval [CI], 3.8%–18.3%) children were smear positive, 23 (30.7%; 95%
CI, 20.5%–42.4%) were LJ positive, 24 (32.0%; 95% CI, 21.7%–43.8%)
were MGIT positive, 25 (33.3%; 95% CI, 22.9%–45.2%) were Xpert
positive, 28 (37.3%; 95% CI, 26.4%–49.3%) were positive by MGIT and
LJ combined, and 32 (42.7%; 95% CI, 31.3%–54.6%) were positive when
all diagnostic tests were combined. Abbreviations: Smear, sputum smear
microscopy after Ziehl-Neelsen staining; LJ, Lowenstein-Jensen culture
on solid media, speciation result included; MGIT, BACTEC MGIT 960 liquid
culture, speciation result included; Xpert, Xpert MTB/RIF assay.
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to 3 years ensured that the participating children were reliably
categorized into the 4 diagnostic classes.
The accuracy data of Xpert in smear-positive (100% sensi-
tivity) and smear-negative (66.6% sensitivity) culture-confirmed
tuberculosis cases were similar to data published for hospitalized
children in South Africa [23]. In both pediatric study cohorts,
Xpert flagged 75% of all culture-confirmed cases. However, the
majority of children in this study were diagnosed with tuber-
culosis on clinical grounds. Due to its low sensitivity in children,
culture is an imperfect reference standard to compare if new,
potentially more sensitive, diagnostic tests are evaluated. Xpert
detected 4 additional cases among the children with clinical
tuberculosis diagnosis. Based on the high specificity of Xpert
in children without tuberculosis and the criteria for a clinical
tuberculosis diagnosis in this study, these 4 additional cases
can be considered as correctly diagnosed. However, when
looking at the total number of children with tuberculosis,
even the combination of Xpert and culture reached only un-
satisfactory sensitivity, which rendered tuberculosis diagnosis
still dependent on clinical judgment in most cases.
As reported elsewhere [13, 23, 31], we also demonstrated that
in children, multiple sampling seems to be required to achieve
reasonable sensitivity, regardless of the type of investigated
specimen and the test under evaluation. Specifically for Xpert,
our data showed incremental yields of 20% and 13% for the
second and third samples, respectively. In the study by Nicol
et al [23], sensitivity was increased by 27.8% by testing a second
sample with Xpert in children with smear-negative results
only. A third sample was not evaluated. Notably, by testing
2 induced sputum samples, the same sensitivity was reached
with Xpert as in our study in which 3 samples were collected in
most children. Although less tolerated by older children, the data
from the study by Nicol et al and also from our study suggest
that a consequent implementation of sputum induction could
increase Xpert’s sensitivity.
More importantly, in concordance with our own results in
adults [21] and data from Boehme et al [22], HIV status did not
influence the diagnostic performance of Xpert in children.
Surprisingly, and contrary to our data, the study by Nicol et al
showed a 100% Xpert sensitivity in HIV-infected children [23].
In terms of identifyingM. tuberculosis in sputum samples of
the 75 children with a tuberculosis diagnosis, both culture and
Xpert showed very comparable sensitivity: solid culture de-
tected 23 cases (30.7%), MGIT detected 24 cases (32.0%), and
Xpert detected 25 cases (33.3%). The generally low myco-
bacterial load in respiratory samples of children seems to be
the limiting factor for all assays. Therefore, the diagnostic
potential of Xpert in other types of specimens—such as gastric
lavage, stool, urine, blood, or fine-needle aspiration from
lymph nodes that may contain a higher number of myco-
bacteria or are easier to obtain—should be explored further.
However, the most relevant finding of this study is that the
use of the Xpert assay has the potential to shorten time to
tuberculosis diagnosis and thus to treatment initiation. With
7 smear-positive but 25 Xpert-positive results among children
in our cohort, Xpert has more than tripled the number of
cases with an early tuberculosis diagnosis.
We also observed a marked but not significant difference in
mortality between classes I and II (Table 1). However, while
applying multiple regression analysis in this small number of
samples, we were not able to identify time to treatment or any
other clinical factor that was associated with mortality.
We demonstrated that the addition of Xpert to the pediatric
diagnostic algorithm would not only increase the overall
number of microbiologically detected cases, but it would also
shorten time to diagnosis. Compared with adults, this effect is
more significant in children because the paucibacillary nature
of pediatric tuberculosis infection leads to lower initial smear-
positivity rates than those seen in adults.
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